Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models

In combination cancer immunotherapies, consideration should be given to designing treatment schedules that harmonize with the immune system’s natural timing. An efficacious temporally programmed combination therapy of extended half-life interleukin 2 (eIL2), tumor targeting antibody, and interferon...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncoimmunology
Asıl Yazarlar: Rothschilds, Adrienne, Tzeng, Alice, Mehta, Naveen K., Moynihan, Kelly D., Irvine, Darrell J., Wittrup, K. Dane
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2019
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492973/
https://ncbi.nlm.nih.gov/pubmed/31069130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1558678
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller